Ovarian Cancer

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses combination treatments currently being tested for the treatment of patients with ovarian cancer.

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

PARP inhibition is quickly becoming a major element of the overall ovarian cancer treatment landscape, as several of these agents are continuing to advance through clinical development.

As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the current status of immune targeting as potential treatment for patients with ovarian cancer.

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Single-agent olaparib significantly improved progression-free survival compared with placebo in the maintenance setting for patients with advanced BRCA-positive ovarian cancer.

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

An interim analysis of an ongoing study showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.

The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

The first trial evaluating the efficacy of abiraterone in patients with ovarian cancer has been halted early due to low response, according to results from the CORAL phase II trial, which were presented at the European Society for Medical Oncology Congress.

Robert C. Bast Jr, MD, who led the development of the first clinically relevant blood-based biomarker for ovarian cancer, was honored in the Gynecologic Malignancies category with a 2015 Giants of Cancer Care® award, a program that OncLive launched to recognize leaders in the field.

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.

A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the most important factors of bilateral salpingo-oophorectomy (BSO) to convey to patients with ovarian cancer.

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

The FDA has granted a fast track designation to niraparib, allowing the initiation of a rolling submission of data for potential approval for the PARP inhibitor as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).